EMA Prepares for Brexit


Applied Clinical Trials

The European Medicines Agency (EMA) has revealed details of its plan to deal with the uncertainty and workload implications linked to the UK’s withdrawal from the European Union (EU) and the agency’s relocation.

“Preparing for the move, managing the necessary changes, and addressing challenges such as possible losses in skilled and experienced staff, in a proactive and efficient way requires considerable internal resources,” said Noel Wathion, EMA’s Deputy Executive Director and head of EMA’s Brexit task force. “With the business continuity plan we aim to ensure that the assessment of medicines is not disrupted and that patients in Europe continue to have access to high quality, safe and effective medicines.”

In May, EMA started to scale back on its so-called category 3 activities, thereby freeing up 43 staff by the end of 2017 who are focusing on the preparations for the UK’s withdrawal from the EU and EMA’s relocation.

The agency decided to stop work temporarily on three areas: the development of the European Medicines Web Portal, a new publicly available online information source on all medicines marketed in the EU; the e-submission project that will allow applicants to electronically submit documents linked to authorization requests for human and veterinary medicines; the development of a transparency roadmap for EMA that lays out future transparency measures; and participation in the benchmarking of medicines regulatory authorities in the EU as of 2018.

In addition, EMA reduced the number of audits as well as some corporate governance and support activities. It has restricted participation of staff in external meetings or conferences and cut back on its own meetings and workshops.

According to the EMA statement, “These types of activities can be put on hold for some time to free up or channel resources into core activities that need to be maintained under any circumstances. However, mid-to-long-term EMA will need to analyze how long these activities can be put on hold before they start to seriously undermine the quality of the Agency’s work and its planning, and the expectations of stakeholders.”

Category 2 activities consist of the proactive publication of clinical data, and various initiatives aimed at promoting availability of medicines as well as some political priorities of the EU, such as EMA’s contribution to the fight against antimicrobial resistance or interactions with health technology assessment (HTA) bodies. These activities will be maintained for as long as possible, workload and staffing situation permitting, the agency continued.

Category 1 includes the highest priority activities that are either directly related to the assessment and safety monitoring of medicines or vital to maintaining the infrastructure of the European regulatory system for medicines, including for example the coordination of actions to protect the safety of patients, inspections across the EU or maintenance of the functionality, and security of critical IT applications.

“It is absolutely crucial to uphold these activities as any disruption would almost immediately have a detrimental effect on the health and well-being of citizens in Europe and would also jeopardize production and distribution of medicines in the EU,” noted the agency. “Further iterations of the business continuity plan will also take into account various scenarios for staff losses and how these may affect the delivery of category 1 and 2 activities. Unexpected higher, faster, or more permanent loss of staff as a consequence of the Agency’s relocation may lead to a situation in which EMA’s operations can no longer be maintained.”

EMA said it will provide further updates on the implementation of its business continuity plan as necessary.




Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Related Content
© 2024 MJH Life Sciences

All rights reserved.